Upregulation of vascular endothelial growth factor by cobalt chloride- simulated hypoxia is mediated by persistent induction of cyclooxygenase-2 in a metastatic human prostate cancer cell line

Clinical and Experimental Metastasis

Volumn 17, Issue 8, 1999, Pages 687-694

  Liu, Xin Hua ^a   Kirschenbaum, Alexander ^a   Yao, Shen ^a   Stearns, Mark E ^b   Holland, James F ^a   Claffey, Kevin ^c   Levine, Alice C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Angiogenesis; Cobalt chloride simulated hypoxia; Cyclooxygenase 2; Metastasis; NS398; Prostaglandin E2; Prostate cancer; Vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; COBALT CHLORIDE; CYCLOOXYGENASE 2; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN E2; VASCULOTROPIN;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL HYPOXIA; CONTROLLED STUDY; ENZYME INDUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MALE; METASTASIS; NORTHERN BLOTTING; PROSTAGLANDIN SYNTHESIS; PROSTATE CANCER; PROTEIN SECRETION; TUMOR VASCULARIZATION;

ANDROGENS; CELL HYPOXIA; COBALT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DRUG INTERACTIONS; ENDOTHELIAL GROWTH FACTORS; ENZYME INDUCTION; HUMANS; ISOENZYMES; LYMPHOKINES; MALE; MEMBRANE PROTEINS; NEOPLASM METASTASIS; NEOPLASMS, HORMONE-DEPENDENT; NITROBENZENES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTATIC NEOPLASMS; STIMULATION, CHEMICAL; SULFONAMIDES; TUMOR CELLS, CULTURED; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033366794     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006728119549     Document Type: Article

References (38)

1. 1. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
2. 2. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76: 839-85.
3. 3. Wang GL, Semenza GL. Characterization of hypoxia-inducible factor-1 and regulation of DNA binding activity by hypoxia. J Biol Chem 1993; 268: 21513-8.
4. 4. Guillemin K, Krasnow MA. The hypoxic response: Huffing and HIFing. Cell 1997; 89: 9-12.
5. 5. Damert A, Ikeda E, Risau W. Activator-protein-1 binding potentials the hypoxia-inducible factor-1 mediated hypoxia-induced transcriptional activation of vascular endothelial growth factor expression in C6 glioma. Biochem J 1997; 327: 419-23.
6. 6. Taketo MM. Cyclooxygenase-2 inhibitor in tumorigenesis (Part II). J Natl Cancer Inst 1998; 90: 1609-20.
7. 2 in human prostatic carcinoma cells. Br J Cancer 1997; 75: 1111-8.
8. 8. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995; 83: 493-501.
9. 9. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell lines. Cancer Res 1996; 56: 5125-7.
10. 10. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997; 94: 3336-40.
11. 11. Tsujii M, Kawano S, Tsuji S, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998; 93: 705-16.
12. 12. Schmedtji JF Jr., Ji YS, Liu WL et al. Hypoxia induces cyclooxygenase-2 via the NF-kB p65 transcription factor in human vascular endothelial cells. J Biol Chem 1997; 272: 601-8.
13. 2 and angiogenesis. Proc Soc Exp Biol Med 1983; 172: 214-8.
14. 14. Brawer MK, Deering RE, Brown M et al. Predictors of pathologic stage in prostatic carcinomas: The role of neovascularity. Cancer 1994; 73: 678-87.
15. 15. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-9.
16. 16. Lissbrant IF, Stattin P, Damber JE, Bergh A. Vascular density is a predictor of cancer-specific survival in prostatic carcinoma. Prostate 1997; 33: 38-45.
17. 17. Toi M, Hoshina S, Takayanagi T, Tominaga T. Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer. Jpn J Cancer Res 1994; 85: 1045-52.
18. 18. Mattern J, Koomagi R, Volm M. Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumor cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996; 73: 931-9.
19. 19. Connolly JM, Rose DP. Angiogenesis in two human prostate cancer cell lines with differing metastatic potential when growing as solid tumors in nude mice. J Urol 1998; 160: 932-6.
20. 20. Connolly JM, Rose DP. A comparison of the expression of the malignant phenotype in two androgen-independent human prostate cancer cell lines after ortholopic implantation in nude mice. Int J Oncol 1997; 11: 771-6.
21. 21. Goldberg MA, Schneider TJ. Similarities between the oxygen-sensing mechanisms regulating the expression of vascular endothelial growth factor and erythropoietin. J Biol Chem 1994; 269: 4355-9.
22. 22. Wang M, Stearns ME. Isolation and characterization of PC-3 human prostate, tumor sublines which preferentially metastasize to select organs in SCID mice. Differentiation 1991; 48: 115-25.
23. 23. Levine AC, Liu XH, Greenberg PD et al. Androgens induce the expression of vascular endothelial growth factor in human fetal prostatic fibroblasts. Endocrinology 1998; 139: 4672-8.
24. 24. Nie DT, Hillman GG, Geddes T et al. Platelet-type 12-lipoxygenase in a human prostate carcinoma stimulates angiogenesis and tumor growth. Cancer Res 1998; 58: 4047-51.
25. 25. Yang M, Sytkowski AJ. Cloning differentially expressed genes by linker capture subtraction. Anal Biochem 1996; 237: 109-14.
26. 26. Shweiki D, Itin A, Soffer D, Kesher E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis. Nature (London) 1992; 359: 843-5.
27. 27. Damert A, Machein M, Breier G et al. Upregulation of vascular endothelial growth factor expression in a rat glioma is conferred by two distinct hypoxia-driven mechanisms. Cancer Res 1997; 57: 3860-4.
28. v-src-transformed 3T3 fibroblasts. Proc Natl Acad Sci USA 1990; 87: 3373-7.
29. 29. Rolland PH, Martin PM, Jacquemier J et al. Prostaglandins in human breast cancer: evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplaslic cells. J Natl Cancer Inst 1980; 64: 1061-70.
30. 30. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1994; 12: 5447-54.
31. 31. Appleby SB, Ristimaki A, Neilson K et al. Structure of the human cyclooxygenase-2 gene. Biochem J 1994; 302: 723-7.
32. 32. Kraemer SA, Arthur KA, Dension MS et al. Regulation of prostaglandin endoperoxide H synthase-2 expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Arch Biochem Biophys 1996; 330: 319-28.
33. 1 in osteoblasts. J Clin Invest 1994; 93: 2490-6.
34. 34. Ben-Av P, Crofford LJ, Wilder RL, Hla T. Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1 : A potential mechanism for inflammatory angiogenesis. FEBS Lett 1995; 372: 83-7.
35. 35. Warner TD, Giuliano F, Vojnovic I et al. Nonsteroid drug selectivities for cyclooxygenase-1 rather than cyclooxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci USA 1999; 96: 7563-8.
36. 36. Masferrer JL, Zweifel BS, Manning PT et al. Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. Proc Natl Acad Sci USA 1994; 91: 3228-32.
37. 37. Futaki N, Yoshikawa K, Hamasaka Y et al. NS398, a novel nonsteroidal anti-inflammatory drug with potent analgestic and antipyretic effects, which causes minimal stomach lesions. Gen Pharmacol 1993; 24: 105-10.
38. 38. Lin XH, Yao S, Kirschenbaum A, Levine AC. NS398, a selective cyclooxygen-ase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res 1998; 58: 4245-9.